The Lancet Haematology

@TheLancetHaem

The Lancet Haematology is a world-leading #haematology journal publishing peer-reviewed research and reviews, opinion, and news. #hematology

London, NY, Beijing

Joined June 2014

2KFollowing

21KFollowers

The Lancet Haematology@TheLancetHaem · Jul 16

🔥DREAMM-7 trial updates (R/R multiple myeloma) 1⃣Sustained overall survival benefit with BVd vs DVd at 39.4 months @TheLancetOncol 👇 shorturl.at/f98Pr 2⃣Stable patient-reported quality of life over 28.2 months @TheLancetHaem 👇 shorturl.at/BYLay @dra_v_hungria

3.0K

The Lancet Haematology Retweeted

Kai Rejeski@KRejeski · Jul 2

Can off-the-shelf iPSC-derived NK cells change the game for B-cell lymphoma? @tix_tobi and I had the opportunity to reflect on an early-phase study by Strati et al, published in @TheLancetHaem , studying FT516—a non-CAR-bearing, iPSC-derived NK-cell Tx. thelancet.com/journals/lanha…

1.0K

The Lancet Haematology@TheLancetHaem · Jul 2

🩸July issue! Trials on avatrombopag for ITP, NK-cell therapy for R/R B-cell lymphoma, bexmarilimab+azacitidine for MDS & R/R AML & SC blinatumomab for R/R B-cell acute lymphoblastic leukaemia Cover on lymphoma collaborative groups! Issue here 👉shorturl.at/9645R

TheLancetHaem's tweet image. 🩸July issue!

Trials on avatrombopag for ITP, NK-cell therapy for R/R B-cell lymphoma, bexmarilimab+azacitidine for MDS &amp; R/R AML &amp; SC blinatumomab for R/R B-cell acute lymphoblastic leukaemia

Cover on lymphoma collaborative groups!

Issue here 👉shorturl.at/9645R

1.0K

The Lancet Haematology@TheLancetHaem · Jun 30

📢Final BELLINI results at 45.6 months follow-up show no overall survival benefit of venetoclax in the general relapsed or refractory multiple myeloma population. Post-hoc analyses suggest benefits are limited to biomarker-positive subgroups. 👇 shorturl.at/bwOYn

6.0K

The Lancet Haematology@TheLancetHaem · Jun 18

Attending #18ICML? Looking forward to the opening ceremony!

737

The Lancet Haematology@TheLancetHaem · Jun 17

🛫On your way to #18ICML in Lugano? Daniela Marín-Hernández, Senior Editor, invites you to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.ly/Q01McRRH0

TheLancetHaem's tweet image. 🛫On your way to #18ICML in Lugano?

Daniela Marín-Hernández, Senior Editor, invites you to reach out with enquiries.

Explore our scope, reach &amp; impact, commitment to publishing excellence, &amp; more: hubs.ly/Q01McRRH0

847

The Lancet Haematology Retweeted

Eddie Cliff@Eddie_Cliff · Jun 15

Listening for the journey home - new @TheLancetHaem podcast featuring a discussion of our commission on adverse events in haematology open.spotify.com/episode/5kT1Ya… #EHA2025

3.0K

The Lancet Haematology@TheLancetHaem · Jun 15

🔥Just presented at #EHA2025! Dr. Elias Jabbour presented promising safety & activity of subcutaneous #blinatumomab in relapsed/refractory ALL ✔️ Two dose regimens tested 💉 Phase 2 dose selected 🏠 Potential for homecare, no central line needed 👇 tinyurl.com/5ckwe6e5

$TheLancetHaem's tweet image. 🔥Just presented at #EHA2025! Dr. Elias Jabbour presented promising safety &amp; activity of subcutaneous #blinatumomab in relapsed/refractory ALL ✔️ Two dose regimens tested 💉 Phase 2 dose selected 🏠 Potential for homecare, no central line needed 👇 tinyurl.com/5ckwe6e5$

3.0K

The Lancet Haematology@TheLancetHaem · Jun 13

🎧Tune in now to hear the authors’ insights directly open.spotify.com/episode/5kT1Ya…

AAmylou Dueck, PhD@BiostatGirl · Jun 13

For those missing the #EHA2025 fun, a #podcast discussing the @TheLancetHaem Commission topic of better adverse event assessment was just posted! buzzsprout.com/1564352/episod… @BroeckelmannPJ @majorajay, @GitaThanaMD (also features Vishal Bhatnagar & Lan-Lan Smith not on X)

1.0K